Yu-Waye Chu, the Chief Medical Officer of $CTMX, sold 21,279 shares of the company on 03-17-2026 for an estimated $136,675. We received data on the trade from a recent SEC filing. This was a sale of approximately 10.1% of their shares of this class of stock. Following this trade, they now own 189,446 shares of this class of $CTMX stock.
$CTMX Insider Trading Activity
$CTMX insiders have traded $CTMX stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $CTMX stock by insiders over the last 6 months:
- SEAN A. MCCARTHY (CEO) has made 0 purchases and 2 sales selling 220,762 shares for an estimated $1,226,043.
- MARCIA BELVIN (SVP, Chief Scientific Officer) sold 31,492 shares for an estimated $202,273
- YU-WAYE CHU (Chief Medical Officer) sold 21,279 shares for an estimated $136,675
- CHRISTOPHER OGDEN (Chief Financial Officer) sold 19,323 shares for an estimated $124,111
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CTMX Hedge Fund Activity
We have seen 73 institutional investors add shares of $CTMX stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC removed 11,065,662 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $47,139,720
- FMR LLC added 9,291,909 shares (+60.4%) to their portfolio in Q4 2025, for an estimated $39,583,532
- FRANKLIN RESOURCES INC removed 5,769,230 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $18,403,843
- KYNAM CAPITAL MANAGEMENT, LP added 5,319,574 shares (+145.9%) to their portfolio in Q4 2025, for an estimated $22,661,385
- ORBIMED ADVISORS LLC removed 4,935,850 shares (-58.3%) from their portfolio in Q4 2025, for an estimated $21,026,721
- STATE STREET CORP added 4,495,949 shares (+697.1%) to their portfolio in Q4 2025, for an estimated $19,152,742
- FAIRMOUNT FUNDS MANAGEMENT LLC removed 3,896,582 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $12,430,096
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CTMX Analyst Ratings
Wall Street analysts have issued reports on $CTMX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 03/18/2026
- Piper Sandler issued a "Overweight" rating on 01/20/2026
- Guggenheim issued a "Buy" rating on 01/20/2026
- Barclays issued a "Overweight" rating on 01/20/2026
- Cantor Fitzgerald issued a "Overweight" rating on 09/22/2025
To track analyst ratings and price targets for $CTMX, check out Quiver Quantitative's $CTMX forecast page.
$CTMX Price Targets
Multiple analysts have issued price targets for $CTMX recently. We have seen 8 analysts offer price targets for $CTMX in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Etzer Darout from Barclays set a target price of $16.0 on 03/19/2026
- Michael Schmidt from Guggenheim set a target price of $15.0 on 03/18/2026
- Roger Song from Jefferies set a target price of $16.0 on 03/18/2026
- Robert Driscoll from Wedbush set a target price of $11.0 on 03/17/2026
- Anupam Rama from JP Morgan set a target price of $12.0 on 03/16/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $17.0 on 03/16/2026
- Olivia Brayer from Cantor Fitzgerald set a target price of $10.0 on 02/04/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
